To immunosuppress: whom, when and how? That is the question with COVID-19
- PMID: 32753413
- PMCID: PMC7456547
- DOI: 10.1136/annrheumdis-2020-218694
To immunosuppress: whom, when and how? That is the question with COVID-19
Keywords: arthritis; biological therapy; glucocorticoids; rheumatoid.
Conflict of interest statement
Competing interests: KLW reports personal fees from Pfizer, AbbVie, Union Chimique Belge (UCB), Eli Lilly & Company, Galapagos, GlaxoSmithKline (GSK), Roche, and Gilead and reports research grants from BMS, Pfizer, outside the submitted work.
Comment on
-
Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study.Ann Rheum Dis. 2020 Sep;79(9):1143-1151. doi: 10.1136/annrheumdis-2020-218479. Epub 2020 Jul 20. Ann Rheum Dis. 2020. PMID: 32719045 Free PMC article. Clinical Trial.
References
-
- Ramiro S, Mostard RLM, Magro-Checa C, et al. . Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the chiC study. Ann Rheum Dis 2020;79:1142–50. 10.1136/annrheumdis-2020-218479 - DOI - PMC - PubMed
-
- Faleck DM, Shmidt E, Huang R, et al. . Effect of concomitant therapy with steroids and tumor necrosis factor antagonists for induction of remission in patients with Crohn's disease: a systematic review and pooled meta-analysis. Clin Gastroenterol Hepatol 2020. doi:10.1016/j.cgh.2020.06.036. [Epub ahead of print: 19 Jun 2020]. - DOI - PMC - PubMed
-
- Rosenbaum JT, Hamilton H, Choi D, et al. . . biologics, spondylitis and COVID-19. Ann Rheum Dis 2020. - PubMed
Publication types
MeSH terms
Substances
Supplementary concepts
LinkOut - more resources
Full Text Sources
Medical
